🇺🇸 FDA
Pipeline program

MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet

3124001

Phase 2 small_molecule active

Quick answer

MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet for Metastatic castration-resistant prostate cancer. is a Phase 2 program (small_molecule) at Orion with 1 ClinicalTrials.gov record(s).

Program details

Company
Orion
Indication
Metastatic castration-resistant prostate cancer.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials